The safety of zoledronic acid

被引：28

作者：

Lipton, Allan ^{[1
]}

机构：

[1] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA

来源：

EXPERT OPINION ON DRUG SAFETY | 2007年 / 6卷 / 03期

关键词：

bisphosphonate; bone metastasis; osteonecrosis of the jaw; renal function;

D O I：

10.1517/14740338.6.3.305

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Zoledronic acid has been marketed for the past 5 years for the treatment of hypercalcemia of malignancy and malignant bone disease in patients with multiple myeloma or a broad range of solid tumors. The safety profile of zoledronic acid in this patient population is well established from the databases of several large, randomized, Phase III trials and postmarketing clinical experience. Zoledronic acid is well tolerated, with predictable side effects, primarily transient flu-like symptoms, which are manageable with standard treatment. Renal monitoring is recommended, with dose reductions for patients with renal dysfunction. Monitoring for electrolyte imbalance is also important as is calcium and vitamin D supplementation. Ocular complications are rare, and osteonecrosis of the jaw is uncommon and might be avoidable with appropriate dental care.

引用

页码：305 / 313

页数：9

共 54 条

[41] A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma [J].

Saad, F ;

Gleason, DM ;

Murray, R ;

Tchekmedyian, S ;

Venner, P ;

Lacombe, L ;

Chin, JL ;

Vinholes, JJ ;

Goas, JA ;

Chen, B .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (19) :1458-1468

[42] Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer [J].

Saad, F ;

Gleason, DM ;

Murray, R ;

Tchekmedyian, S ;

Venner, P ;

Lacombe, L ;

Chin, JL ;

Vinholes, JJ ;

Goas, JA ;

Zheng, M .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (11) :879-882

[43]

SAAD F, 2003, AM UR ASS ANN M CHIC

[44]

SAAD F, 2006, 2006 PROST CANC S MU, P168

[45] Management of the adverse effects associated with intravenous bisphosphonates [J].

Tanvetyanon, T. ;

Stiff, P. J. .

ANNALS OF ONCOLOGY, 2006, 17 (06) :897-907

[46] First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma [J].

Tosi, P ;

Zamagni, E ;

Cellini, C ;

Parente, R ;

Cangini, D ;

Tacchetti, P ;

Perrone, G ;

Ceccolini, M ;

Boni, P ;

Tura, S ;

Baccarani, M ;

Cavo, M .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 76 (05) :399-404

[47] Bisphosphonates and osteonecrosis of the jaw:: cause and effect or a post hoc fallacy? [J].

Van den Wyngaert, T. ;

Huizing, M. T. ;

Vermorken, J. B. .

ANNALS OF ONCOLOGY, 2006, 17 (08) :1197-1204

[48]

VOGEL CL, 2003, P AN M AM SOC CLIN, V22, P754

[49] Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer [J].

Vordos, D ;

Paule, B ;

Vacherot, F ;

Allory, Y ;

Salomon, L ;

Hoznek, A ;

Yiou, R ;

Chopin, D ;

Abbou, CC ;

de la Taille, A .

BJU INTERNATIONAL, 2004, 94 (04) :524-527

[50] The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer [J].

Weinfurt, KP ;

Li, Y ;

Castel, LD ;

Saad, F ;

Timbie, JW ;

Glendenning, GA ;

Schulman, KA .

ANNALS OF ONCOLOGY, 2005, 16 (04) :579-584

← 1 2 3 4 5 6 →